Deborah Mukherji· @dmukherji · X·· 2 天前评分70
正文 · 原文
More on ctDNA as a dynamic biomarker in prostate cancer at #ESMO26 @AzadOncology @OncoAlert
In TALAPRO-3, ctDNA tumour fraction clearance at week 5 was higher with talazoparib + enzalutamide (82% vs 68%) and associated with longer rPFS.
215 浏览 · 4 赞 · 4 转发 · 0 回复
会议摘要
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.org来源：Deborah Mukherji · x.com